Major heat shock protein Hsp72 controls oncogene-induced senescence

Annals of the New York Academy of Sciences

Volumn 1197, Issue , 2010, Pages 152-157

  Sherman, Michael ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Heat shock; Oncogenes; Senescence

Indexed keywords

HEAT SHOCK PROTEIN 72; PROTEIN P53;

CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; CONFERENCE PAPER; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SENESCENCE; UPREGULATION;

EID: 77953225311     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05196.x     Document Type: Conference Paper

References (63)

1. Hahn,W.C. 2005. Telomere and telomerase dynamics in human cells. Curr. Mol. Med. 5: 227-231.
2. Stewart, S.A. & R.A. Weinberg. 2006. Telomeres: cancer to human aging. Annu. Rev. Cell Dev. Biol. 22: 531-557.
3. Chen, J. & M.S. Goligorsky. 2006. Premature senescence of endothelial cells: Methusaleh's dilemma. Am. J. Physiol. Heart Circ. Physiol. 290: H1729-H1739.
4. Brandes, R.P., I. Fleming & R. Busse. 2005. Endothelial aging. Cardiovasc. Res. 66: 286-294.
5. Fehrer, C. & G. Lepperdinger. 2005. Mesenchymal stem cell aging. Exp. Gerontol. 40: 926-930.
6. Sherr, C.J. et al. 2005. p53-dependent and -independent functions of the Arf tumor suppressor. Cold Spring Harbor Symp. Quant. Biol. 70: 129-137.
7. Piacibello, W., L. Gammaitoni & Y. Pignochino. 2005. Proliferative senescence in hematopoietic stem cells during ex-vivo expansion. Folia Histochem. Cytobiol. 43: 197-202.
8. Chen, J. 2005. Senescence of hematopoietic stem cells and bone marrow failure. Int. J. Hematol. 82: 190-195.
9. Jacobs, J.J. & T. de Lange. 2005. p16INK4a as a second effector of the telomere damage pathway. Cell Cycle 4: 1364-1368.
10. Ben-Porath, I. & R.A. Weinberg. 2005. The signals and pathways activating cellular senescence. Int. J. Biochem. Cell Biol. 37: 961-976.
11. Sharpless, N.E. 2004. Ink4a/Arf links senescence and aging. Exp. Gerontol. 39: 1751-1759.
12. Roninson, I.B. 2002. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 179: 1-14.
13. Roninson, I.B. 2003. Tumor cell senescence in cancer treatment. Cancer Res. 63: 2705-2715.
14. Parkinson, E.K. et al. 2000. Replicative senescence as a barrier to human cancer. Biochem. Soc. Trans. 28: 226-233.
15. McCormick, J.J. & V.M. Maher. 1988. Towards an understanding of the malignant transformation of diploid human fibroblasts. Mutat. Res. 199: 273-291.
16. Vogelstein,B.&K.W.Kinzler. 1993. Themultistep nature of cancer. Trends Genet. 9: 138-141.
17. Wright, W.E. & J.W. Shay. 2001. Cellular senescence as a tumor-protection mechanism: the essential role of counting. Curr. Opin. Genet. Dev. 11: 98-103.
18. Campisi, J. 2005. Aging, tumor suppression and cancer: high wire-act! Mech. Ageing Dev. 126: 51-58.
19. Hanahan, D. & R.A. Weinberg. 2000. The hallmarks of cancer. Cell 100: 57-70.
20. Garbe, J.C. et al. 2007. Inactivation of p53 function in cultured human mammary epithelial cells turns the telomere-length dependent senescence barrier from agonescence into crisis. Cell Cycle 6: 1927-1936.
21. Li, Y. et al. 2007. Transcriptional changes associated with breast cancer occur as normal human mammary epithelial cells overcome senescence barriers and become immortalized. Mol. Cancer 6: 7.
22. Shay, J.W. & S. Bacchetti. 1997. A survey of telomerase activity in human cancer. Eur. J. Cancer 33: 787-791.
23. Kim, N.W. et al. 1994. Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015.
24. Matsuda, Y. 2008.Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma. World J. Gastroenterol. 14: 1734-1740.
25. Schwabe, M. & M. Lubbert. 2007. Epigenetic lesions in malignant melanoma. Curr. Pharm. Biotechnol. 8: 382-387.
26. Chang, B.D. et al. 1999. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 18: 4808-4818.
27. Chang, B.D. et al. 1999. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 59: 3761-3767.
28. Lowe, S.W., E. Cepero & G. Evan. 2004. Intrinsic tumour suppression. Nature 432: 307-315.
29. Narita,M. & S.W. Lowe. 2004. Executing cell senescence. Cell Cycle 3: 244-246.
30. Sebastian, T. & P.F. Johnson. 2006. Stop and go: antiproliferative and mitogenic functions of the transcription factor C/EBP. Cell Cycle 5: 953-957.
31. Benanti, J.A. & D.A. Galloway. 2004. The normal response to RAS: senescence or transformation? Cell Cycle 3: 715-717.
32. Mason, D.X., T.J. Jackson & A.W. Lin. 2004. Molecular signature of oncogenic ras-induced senescence. Oncogene 23: 9238-9246.
33. Peeper, D.S. et al. 2001. Escape from premature senescence is not sufficient for oncogenic transformation by Ras. Nat. Cell Biol. 3: 198-203.
34. Chen, Z. et al. 2005. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436: 725-730.
35. Olsen, C.L. et al. 2002. Raf-1-induced growth arrest in human mammary epithelial cells is p16-independent and is overcome in immortal cells during conversion. Oncogene 21: 6328-6339.
36. Zhu, J. et al. 1998. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 12: 2997-3007.
37. Di Micco, R. et al. 2006. Oncogene-induced senescence is a DNA damage response triggered by DNA hyperreplication. Nature 444: 638-642.
38. Bihani,T. et al. 2004. Differential oncogenicRas signaling and senescence in tumor cells. Cell Cycle 3: 1201-1207.
39. Yaswen, P. & J. Campisi. 2007. Oncogene-induced senescence pathways weave an intricate tapestry. Cell 128: 233-234.
40. Han, J. & P. Sun. 2007. The pathways to tumor suppression via route p38. Trends Biochem. Sci. 32: 364-371.
41. Denoyelle, C. et al. 2006. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat. Cell Biol. 8: 1053-1063.
42. Lee, S.H. et al. 2009. Blocking of p53-Snail binding, promoted by oncogenic K-Ras, recovers p53 expression and function. Neoplasia 11: 22-31.
43. Ansieau, S. et al. 2008. Induction of EMT by Twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 14: 79-89.
44. Rohde, M. et al. 2005. Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms. Genes Dev. 19: 570-582.
45. Daugaard, M., M. Jaattela & M. Rohde. 2005. Hsp70-2 is required for tumor cell growth and survival. Cell Cycle 4: 877-880.
46. Kaul, S.C. et al. 2005. Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides. J. Biol. Chem. 280: 39373-39379.
47. Kaul, S.C. et al. 2003. Overexpressed mortalin (mot- 2)/mthsp70/GRP75 and hTERT cooperate to extend the in vitro lifespan of human fibroblasts. Exp. Cell Res. 286: 96-101.
48. Wadhwa, R. et al. 1998. Inactivation of tumor suppressor p53 bymot-2, a hsp70 familymember. J. Biol.Chem. 273: 29586-29591.
49. Wadhwa, R. et al. 1996. Genetic differences between the pancytosolic and perinuclear forms ofmurinemortalin. Exp. Cell Res. 226: 381-386.
50. Wadhwa, R. et al. 1999. NIH 3T3 cells malignantly transformed by mot-2 show inactivation and cytoplasmic sequestration of the p53 protein. Cell Res. 9: 261-269.
51. Yokoyama, K. et al. 2002. Extended longevity of Caenorhabditis elegans by knocking in extra copies of hsp70F, a homolog of mot-2 (mortalin)/mthsp70/ Grp75. FEBS Lett. 516: 53-57.
52. Wadhwa, R. et al. 2002. Hsp70 family member, mot- 2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. Exp. Cell Res. 274: 246-253.
53. Wadhwa, R. et al. 2000. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res. 60: 6818-6821.
54. Yaglom, J.A., V.L. Gabai & M.Y. Sherman. 2007. High levels of heat shockprotein Hsp72 incancer cells suppress default senescence pathways. Cancer Res. 67: 2373-2381.
55. Nihei, T. et al. 1993. Demonstration of selective protein complexes of p53 with 73 kDa heat shock cognate protein, but not with 72 kDa heat shock protein in human tumor cells. Cancer Lett. 73: 181-189.
56. Ehrhart, J.C. et al. 1988. Specific interaction between a subset of the p53 protein family and heat shock proteins hsp72/hsc73 in a human osteosarcoma cell line. Oncogene 3: 595-603.
57. Miyakoda, M. et al. 2002. Activation of ATM and phosphorylation of p53 by heat shock. Oncogene 21: 1090-1096.
58. McNeill-Blue, C. et al. 2006. Apoptosis mediated by p53 inratneuralAF5 cells following treatmentwith hydrogen peroxide and staurosporine. Brain Res. 1112: 1-15.
59. Das, K.C. & R. Dashnamoorthy. 2004. Hyperoxia activates the ATR-Chk1 pathway and phosphorylates p53 at multiple sites. Am. J. Physiol. Lung CellMol. Physiol. 286: L87-L97.
60. O'Callaghan-Sunol, C., V.L. Gabai & M.Y. Sherman. 2007. Hsp27 modulates p53 signaling and suppresses cellular senescence. Cancer Res. 67: 11779-11788.
61. Gabai,V.L. et al. 2009.Heat shockprotein Hsp72 controls oncogene-induced senescence pathways in cancer cells. Mol. Cell. Biol. 29: 559-569.
62. Dai, C. et al. 2007. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 130: 1005-1018.
63. Min, J.N. et al. 2007. Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors. Oncogene 26: 5086-5097.